Efficacy and safety of azathioprine during remission of immune-mediated thrombotic thrombocytopenic purpura

Blood Adv. 2022 Sep 27;6(18):5463-5466. doi: 10.1182/bloodadvances.2022007632.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • ADAM Proteins
  • ADAMTS13 Protein
  • Azathioprine / adverse effects
  • Humans
  • Purpura, Thrombotic Thrombocytopenic* / drug therapy

Substances

  • ADAM Proteins
  • ADAMTS13 Protein
  • Azathioprine